Literature DB >> 16633049

CC-type chemokine receptor 5-Delta32 mutation protects against primary sclerosing cholangitis.

Liesbet Henckaerts1, Johan Fevery, Werner Van Steenbergen, Chris Verslype, Paul Yap, Frederik Nevens, Tania Roskams, Louis Libbrecht, Paul Rutgeerts, Séverine Vermeire.   

Abstract

BACKGROUND: Primary sclerosing cholangitis (PSC) is commonly associated with inflammatory bowel disease (IBD) and characterized by fibrosing inflammatory destruction of biliary ducts. The pathogenesis of PSC remains unknown, but immunological, bacterial, viral, and toxic factors play a role in a genetically susceptible host. We hypothesized that CC-type chemokine receptor 5 (CCR5) would be an interesting candidate gene for susceptibility to PSC from its chromosomal location within the IBD susceptibility locus on 3p21, as well as from a functional perspective. We therefore investigated the role of the functional 32-bp deletion in this gene (CCR5-Delta32) with regard to susceptibility to PSC.
METHODS: A total of 110 patients with PSC, 56 with concomitant IBD (23 with Crohn's disease, 28 with ulcerative colitis, 5 with indeterminate colitis), were collected. All of the subjects were genotyped for CCR5-Delta32 with polymerase chain reaction amplification, followed by detection on ethidium bromide-stained agarose gel. Genotypes and allele frequencies were compared with a cohort of IBD patients without PSC (n = 400) and healthy control subjects (n = 362).
RESULTS: The frequency of the CCR5-Delta32 mutation in PSC (6.8%) was significantly lower compared with IBD (12.6%; P = 0.016) and healthy control subjects (12.2%, P = 0.026), suggesting a protective effect of this mutation on PSC. None of the PSC patients with severe disease necessitating liver transplantation (n = 17) carried CCR5-Delta32.
CONCLUSIONS: Because an intact CCR5 receptor is needed for internalization of specific pathogens and homing of memory T lymphocytes to the liver, we hypothesize that a deficient expression of this receptor resulting from the CCR5-Delta32 variant may protect against PSC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16633049     DOI: 10.1097/01.MIB.0000209790.21737.28

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  7 in total

1.  The RANTES -28 g polymorphism is associated with primary sclerosing cholangitis.

Authors:  Liesbet Henckaerts; Johan Fevery; Werner Van Steenbergen; Chris Verslype; Frederik Nevens; Paul Yap; Tania Roskams; Paul Rutgeerts; Severine Vermeire
Journal:  Gut       Date:  2007-06       Impact factor: 23.059

Review 2.  Genetic epidemiology of primary sclerosing cholangitis.

Authors:  Tom-H Karlsen; Erik Schrumpf; Kirsten-Muri Boberg
Journal:  World J Gastroenterol       Date:  2007-11-07       Impact factor: 5.742

Review 3.  Pathogenesis of primary sclerosing cholangitis.

Authors:  Marion J Pollheimer; Emina Halilbasic; Peter Fickert; Michael Trauner
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-12       Impact factor: 3.043

4.  Highly specific blockade of CCR5 inhibits leukocyte trafficking and reduces mucosal inflammation in murine colitis.

Authors:  Andrea Mencarelli; Sabrina Cipriani; Daniela Francisci; Luca Santucci; Franco Baldelli; Eleonora Distrutti; Stefano Fiorucci
Journal:  Sci Rep       Date:  2016-08-05       Impact factor: 4.379

5.  Negative association of the chemokine receptor CCR5 d32 polymorphism with systemic inflammatory response, extra-articular symptoms and joint erosion in rheumatoid arthritis.

Authors:  Manuela Rossol; Matthias Pierer; Sybille Arnold; Gernot Keysser; Harald Burkhardt; Christoph Baerwald; Ulf Wagner
Journal:  Arthritis Res Ther       Date:  2009-06-18       Impact factor: 5.156

Review 6.  The immunobiology of primary sclerosing cholangitis.

Authors:  Jonathan H Aron; Christopher L Bowlus
Journal:  Semin Immunopathol       Date:  2009-05-26       Impact factor: 9.623

Review 7.  C-C chemokine receptor type five (CCR5): An emerging target for the control of HIV infection.

Authors:  Fatima Barmania; Michael S Pepper
Journal:  Appl Transl Genom       Date:  2013-05-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.